Codexis (CDXS) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Codexis (CDXS) over the past year, gaining 13.8% versus a loss of 48.7%. Over five years, NERV leads with a -70.2% price change compared with -95.2% for CDXS. Minerva Neurosciences is the larger company by market cap ($153.7 million vs $148.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDXS | NERV |
|---|---|---|
| Share price | $1.36 | $3.22 |
| Market cap | $148.93M | $153.75M |
| 1-day change | -3.55% | -1.53% |
| YTD return | -16.56% | -19.90% |
| 1-year return | -48.68% | +13.78% |
| 5-year return | -95.20% | -70.19% |
| EPS (TTM) | $-0.33 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.98 | $12.46 |
| 52-week low | $0.96 | $2.24 |
| Distance from 52-week high | -54.36% | -74.16% |
| Analyst consensus | buy | none |
| Avg. price target upside | +351.47% | +220.81% |
| Average volume | 1.12M | 183.63K |
| Shares outstanding | 109.51M | 47.75M |
| Employees | 146 | 7 |
| Sector | Industrials | Health Care |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed CDXS by 62.5 percentage points over the past year.
- The two companies sit in different sectors: Codexis in Industrials and Minerva Neurosciences in Health Care.
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CDXS vs NERV FAQ
Which is bigger, Codexis or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $153.75M compared with $148.93M for Codexis (CDXS).
Which stock has performed better over the past year, CDXS or NERV?
NERV returned +13.78% over the past 12 months, compared with -48.68% for CDXS (price return, excluding dividends). Past performance does not predict future results.
Are Codexis and Minerva Neurosciences in the same industry?
No. Codexis is in the Industrials sector, while Minerva Neurosciences is in Health Care.